A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mu
- This topic has 0 replies, 1 voice, and was last updated 4 years, 2 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.
https://meetinglibrary.asco.org/record/186633/abstract
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.